文献速递妇科

子宫内膜癌免疫检查点抑制剂完全缓解后的结局

Outcomes following complete response to immune checkpoint inhibitors in endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2026-07-15

该回顾性单中心研究纳入192例接受免疫治疗的子宫内膜癌患者,57例(29.7%)达完全缓解,其中MMRd 37例、MMRp 20例。中位随访显示多数患者维持无病生存,因非进展原因停药者90%无复发,提示缓解具有持久性。

要点

  • 免疫治疗完全缓解见于MMRd与MMRp子宫内膜癌,MMRd缓解更持久。
  • 57例完全缓解者中37例(64.9%)末次随访仍存活且无病。
  • 因非进展原因停药者90%无复发,支持停药后缓解持久。

核心结论

  • 子宫内膜癌免疫治疗后完全缓解在MMRd和MMRp肿瘤中均可见,MMRd缓解持久性呈更优趋势。
  • 多数完全缓解者末次随访仍无病,包括复发患者在停药后维持缓解至少两年。

研究设计与样本

  • 192例接受免疫治疗的患者中57例(29.7%)达完全缓解,含MMRd 37例(64.9%)和MMRp 20例(35.1%)。
  • 采用Kaplan-Meier法估计时间-事件结局,中位至完全缓解时间7.2个月。

主要发现

  • 67%的患者因复发疾病接受治疗。
  • MMRd中位随访53.5个月、MMRp中位随访21.4个月时,37例(64.9%)仍存活且无病,其中86.5%已停药。
  • 因非进展或死亡原因停药的复发患者30例中,27例(90%)无复发,含5例后来死于无关原因。
  • 停药后3例(10%)出现复发。

临床怎么用

  • 对免疫治疗后达完全缓解的子宫内膜癌患者,尤其MMRd,可考虑在密切随访下停药观察。
  • 复发患者达完全缓解并因非进展原因停药后,仍可能维持持久缓解。

局限性

  • 回顾性单中心设计,样本量有限,MMRp随访时间较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Immune checkpoint inhibitors have transformed treatment for advanced and recurrent endometrial cancer (EC), yet optimal management after complete response (CR) remains unclear. We evaluated clinical outcomes and durability of response among patients with mismatch repair deficient (MMRd) and proficient (MMRp) EC who achieved CR following PD-1/PD-L1-directed immunotherapy. METHODS: We performed a retrospective single-institution study of patients with EC who achieved a CR to immunotherapy between June 2016 and November 2025. Clinical characteristics, treatment details, and outcomes were abstracted from medical records. Time-to-event outcomes were estimated using Kaplan-Meier methods. RESULTS: Among 192 patients with EC treated with immunotherapy, 57 (29.7%) achieved a CR, including 37 (64.9%) with MMRd and 20 (35.1%) with MMRp tumors. Most (67%) received treatment for recurrent disease. Median time to CR was 7.2 months. At a median follow-up of 53.5 months for MMRd and 21.4 months for MMRp disease, 37 patients (64.9%) remained alive and disease-free, 86.5% of whom were off treatment. Among patients with recurrent disease who discontinued immunotherapy for reasons other than progression or death (n = 30), 27 (90%) remained recurrence-free, including five who later died of unrelated causes. Three patients (10%) experienced recurrence after discontinuation. CONCLUSIONS: In this retrospective analysis, CRs to immunotherapy were observed in both MMRd and MMRp EC, with a trend toward greater durability in MMRd tumors. Most patients who achieved CR remained disease-free at last follow-up, including many with recurrent disease who maintained remission for at least two years after treatment discontinuation, supporting the durability of response.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. O'Connor RM, Chalif J, Gonzalez A, et al. Outcomes following complete response to immune checkpoint inhibitors in endometrial cancer. Gynecol Oncol. 2026. PMID: 42456481. doi:10.1016/j.ygyno.2026.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。